Magic mushrooms and mood: exploring Psilocybin as a depression treatment
Maria Rasool, Taha Hannan, Muhammad Imam
Journal of the Pakistan Medical Association December 20, 2025 DOI: 10.47391/jpma.30858 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Letter to the editor Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Topics | Depression Psilocybin Serotonin |
| Keywords | Hallucinogen Depression economics Obsessive compulsive Magic telescope Psychotherapist Perception Psychological therapy Depressive symptoms Altered state |
| Key points | Psilocybin is emerging as a viable treatment option for Major Depressive Disorder and treatment-resistant depression. |
Abstract
Dear Editor, In view of ongoing global research on mental health, especially Major Depressive Disorder, we would like to draw attention to a psychedelic substance, Psilocybin, which has been emerging as a viable treatment option for MDD. Psilocybin is a psychedelic compound derived from certain mushrooms that acts on Serotonergic receptors (primarily 5HT-2A). Psychedelic substances have psychological effects, i.e., hallucinations, euphoria, and altered perception (1). Studies have demonstrated their effectiveness in the treatment of disorders like ‘Major Depressive Disorder (MDD)’, and ‘Treatment-Resistant Depression’. Recently, the FDA gave ‘breakthrough’ therapy status to a psilocybin treatment developed by London-based biotechnology company ‘Compass Pathways Ltd’ as stated in (2).